Celera Genomics, a segment of Applera Corporation, focuses on discovering and developing new therapies using genomics, bioinformatics, proteomics, medicinal chemistry, and biology technology platforms. They have a portfolio of programs targeting coagulation, oncology, and inflammation. Celera Genomics collaborates with Celera Diagnostics to understand genetic variations and their associations with diseases, aiding in the development of diagnostic and therapeutic products. They also develop molecular diagnostic products for disease detection, characterization, monitoring, and treatment selection. Celera has a distribution agreement with Abbott to commercialize a wide range of molecular diagnostic products.